Lymphoma, B-cell Marginal Zone
10 clinical trials · Condition
◉ Watch Lymphoma, B-cell Marginal Zone
| Record | Firm | Date |
|---|---|---|
| Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (NCT05024045) | Eli Lilly and Company | 2021-09-30 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) (NCT04849416) | Eli Lilly and Company | 2021-05-14 |
| AEDV Registry of Primary Cutaneous Lymphoma (NCT03646422) | Fundación Academia Española de Dermatología | 2016-09-01 |
| Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma (NCT03093831) | National Cancer Centre, Singapore | 2016-07-08 |
| Marginal Zone Lymphoma Cohort in Korea (NCT02732236) | Dong-A University Hospital | 2013-03-01 |
| Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas (NCT01263418) | UNC Lineberger Comprehensive Cancer Center | 2011-06-01 |
Track Lymphoma, B-cell Marginal Zone automatically
Every clearance here is in the API, with alerts when new ones post.